PSJ18 WALGREENS Opp Exh 44

Case: 1:17-md-02804-DAP Doc #: 2205-44 Filed: 08/13/19 2 of 22. PageID #: 334176

Message

From: Dymon, Christopher [christopher.dymon@walgreens.com]

Sent: 1/10/2013 4:36:39 PM

To: Osullivan, Lauren [lauren.osullivan@walgreens.com]; Polster, Tasha [tasha.polster@walgreens.com]; Daugherty,

Patricia [patricia.daugherty@walgreens.com]

Subject: DEA Update Presentation For Market Leadership

Attachments: DEA Market Leadership Scrubbed Version Jan 2013.pptx

Hi Lauren,

Please let me know if you are the contact in order to send this presentation out to the Market Leadership group.

Thanks!


Be Well, Chris


Christopher Dymon, PharmD 200 Wilmot Road, MS 2194 Deerfield, IL 60015 p. 847 f. 847




Every day I help people get, stay and live well.


This message, including attachments, is the property of Waigreen Co. or its affiliates. It is intended solely for the individuals or entities to which it is addressed. This resessage may contain information that is proprietary, confidential and subject to attorney-client privilege. If you are not the intended recipient, please immediately notify the sender and delete this message from your system. Any viewing, copying, publishing, disclosure, distribution of this information, or the taking of any action in reliance on the contents of this message by unintended recipients is strictly prohibited.





The new hot topic in the news is the epidemic America has: Prescription Pain Drug Abuse





This particular stat came out of California, but there were multiple examples across the country where the leading cause of accidental death is prescription pain medications (opioid use). This national problem has brought increased scrutiny to physicians, pharmacists and drugs wholesalers from regulators, policy makers and law enforcement.




Title 21 Code of Federal Regulations

Section 1306.04 Purpose of issue of prescription.

(a) A prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. An order purporting to be a prescription issued not in the usual course of professional treatment or in legitimate and authorized research is not a prescription within the meaning and intent of section 309 of the Act (21 U.S.C. 829) and the person knowingly filling such a purported prescription, as well as the person issuing it, shall be subject to the penalties provided for violations of the provisions of law relating to controlled substances.


Proprietary & Confidential, Property of Walgreen Co.

Pharmacists are required by DEA regulations to ensure that prescriptions for controlled substances are dispensed for a legitimate medical purpose. This legal responsibility is pursuant to Title 21 code of Federal regulations. The important point of this regulation is "the corresponding responsibility rests with the pharmacist who fills the prescription"





The key to note is that this isn't just a Florida problem.





Operational Steps Taken

- In June, we re-launched our Good Faith Dispensing Policy across the Chain
- Pilots
 - Target Drug Good Faith Dispensing in FL and NV
 - Prescriber Sanctioning in NJ and PA
 - 8 prescribers total
- Invalid Prescriber DEA removal from IC+

Proprietary & Confidential, Property of Walgreen Co.

We had a COMPASS Communication last week announcing that we are removing Invalid DEAs

What is it?

A new IC+ enhancement is being released this week that will flag and remove Invalid DEA #'s

How will I know the DEA number was removed because it was invalid?

When the prescriber's DEA # is removed, a message will be put in the comment field of the Prescriber Inquiry window that says: WARNING INVALID DEA #. DO NOT ADD DEA #. DO NOT FILL C2-5 Rxs FOR THIS PRESCRIBER.

What do I need to know?

Pharmacy staff must look in the prescriber inquiry window for the message above before adding a DEA #. If the message above is in the profile, do not register the prescriber again and do not add the DEA # back into IC+. Pharmacy staff must verify that the prescriber's DEA number is valid from the DEA website before registering any prescriber. SNet -> RxOps-> Filling Prescriptions -> Good Faith Dispensing -> DEA Diversion Website -> Registration Validation or click link below

(https://www.deadiversion.usdoj.gov/webforms/validateLogin.jsp)


What do I do if this is a refill?

Speak with the patient to ask if they have a new prescriber they would like you to contact for a new prescription. If they do not have a new prescriber, they need to contact their existing prescriber for next steps, as Walgreens cannot fill this prescription under the current prescriber.

What if this is a new prescription?

Return the prescription to the patient and let them know they need to contact the prescriber for next steps.







Customer Service in Regard to GFD Policy

- Intentionally written with grey areas
- •Intended to be used as a guideline
- Does not replace sound professional judgment

Proprietary & Confidential, Property of Walgreen Co.





Suspicious Order Monitoring

How normal and expected transactions are identified:

- Accumulation of Receipts over time period The system accumulates the amount of each controlled substance over the last six weeks.
- Ceiling Limit Data mining is done across Walgreens retail pharmacies to determine the maximum amount that a pharmacy should be allowed to receive in a rolling six week time period, based on statistical linear regression. The analysis compares like pharmacies across the country based on script volume and determines by drug what would represent unusual quantities.

Proprietary & Confidential, Property of Walgreen Co.

DEA regulations require that distributors (i.e.; the Walgreen distribution centers) must take reasonable measures to identify its customers, understand the normal and expected transactions conducted by those customers, and identify transactions that are suspicious in nature. Orders must be assessed to ensure that quantities for controlled substances at a specific location are reasonable. In making such assessments, a wholesale distributor may consider the purchasing entity's clinical business needs, location, and population served. In addition, Walgreens *must report* to the DEA any order that is deemed suspicious.


So the system takes into account normal accumulation for the store over the last 6 weeks and the maximum (a.k.a. ceiling) they should have over a rolling 6 weeks.



SOM as it Applies to Cardinal

- Cardinal will limit the <u>entire family</u> of a drug based on monthly purchases
 - example: HC/APAP, Hydromet, Tussionex is all grouped into one
- Orders they flag (ie; your invoice says "Restricted Due to DEA Regulations") are reported immediately to the DEA
- Cardinal has our sales history by store for the past year, so they can monitor any orders that deviate from the norm
- Anything they deem as suspicious gets cut

Proprietary & Confidential, Property of Walgreen Co.




All receipts count toward the store's rolling six week volume.



Best Practices For Ordering

- Review all Controlled Substance receipts <u>before</u> posting
 - Adjust the shipped quantity to "0" if you did not receive
 - Post as short when appropriate
- On-hands
 - Do not falsely increase/decrease on-hands
 - Do not increase/decrease suggested orders
 - Do not manually inflate your orders

Proprietary & Confidential, Property of Walgreen Co.





- American Pharmaceutical Association (APhA)
- American Academy of Pain Medicine (AAPM)
- American Medical Association (AMA)
- National Association of Chain Drug Stores (NACDS)
- National Association of Boards of Pharmacy (NABP)

Proprietary & Confidential, Property of Walgreen Co.

This is not just a Walgreen issue, this is an industry wide issue. We have been working with or are in conversations with various organizations

Talk to some of the meetings/conversations.....

As we further advance our pharmacy practices to meet these new challenges, we continue to believe that addressing prescription drug abuse will require all parties – including leaders in the community, physicians, pharmacies, distributors and regulators – to play a role in finding practical solutions to combatting abuse while balancing patient access to critical medication

Our goal is to lead the industry to a solution for this problem that affects all areas of healthcare.



Task Forces and Committee Meetings

- If you or your Supervisors are asked to participate
 Yes, we need your help!
- Contact us before agreeing to participate
 - Tasha Polster or Al Cater
 - We will ensure that you are fully versed or have additional corporate support
- This team work will ensure we continue to build relationships with state agencies and remain a leader in the industry

Proprietary & Confidential, Property of Walgreen Co.

Many state regulators or agencies will ask for your participation in different task forces or committees because of the national presence Walgreens brings. We do need your help, but we also want to make sure that the person participating is fully versed on the national issue and not just seeing it from a district, state, or local level. Contact me or Al Carter and we will ensure that you have what you need from corporate before agreeing to participate.

This is an opportunity to make sure that laws and regulations that are created don't hinder us from continuing in expanding our pharmacy practice to the highest level.